An Open Label Two Arm Randomised Clinical Study to Evaluate the Safety and Efficacy of Cystone SF Liquid in diabetic subjects suffering from Chronic Urinary Tract Infections

The Himalaya Drug Company0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Adult male and female subjects aged more than or equal too 18 years presenting atleast two of the following UTI symptoms like urgency, dysuria, frequency of micturition (nos), suprapubic pain, haematuria, burning micturition, fever, flank pain, chills, nausea and emesis.
•Known diabetic subjects with RBS less than or equal to 160 mg/dL.
•UTI as diagnosed by urine culture more than 105 CFU/mL
•Urine routine microscopy suggestive of increase or normal number of pus cells (white blood cells) per cubic millimetre
•Subjects willing to sign informed consent and follow the study procedure.
•Subjects who has not participated in any similar kind of clinical study in the last one month.

•History of neurogenic bladder, pelvic irradiation or chemical cystitis, Presence of urethral, pelvic, or rectal carcinoma, Benign or malignant bladder tumors, Tuberculous cystitis, urinary schistosomiasis.
•Subjects with cardiac, neurological, renal or hepatic dysfunction.
•Pregnant &breast-feeding women.
•Significant medical problems such as uncontrolled hypertension / congestive heart failure or any other medication condition
•History of ongoing, chronic or recurrent infectious disease / lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.
•History of Alcohol or smoking abuse.
•Patients unwilling to provide informed consent or abide by the requirements of the study

发起方